To obtain the subject new compound useful for a medicine for preventing and treating an oculopathy such as especially glaucoma or hypertonia bulbi.
This compound is shown by the formula [A is a ethylene, vinylene, etc.; R1 is a 3-8C alkyl, a 3-8C alkenyl, etc.; R2 and R3 are each H or an acryl; X is CH2, O, etc.; Z is OR4, NHCOR5 (R4 and R5 are each H, an alkyl, etc.)] such as 16-(3,5-dichlorophenoxy)-15-deoxy-15-fluoro-17,18,19,20- tetranorprostaglandin F2α methyl ester. The compound is obtained by synthesizing a prostaglandin skeleton by a general prostaglandin F2α synthesizing method, converting a hydroxyl group at the 15-position into a fluorine atom by a fluorination reaction. The compound is administered in 0.001 to 5(weight/ volume)% once to several times daily in the case of an eye drop.
KAGEYAMA MASAAKI
MORI NOBUAKI
SAKATA KAZUHISA
NAKANO TAKASHI
MATSUMURA YASUSHI
MORISAWA YOSHITOMI
ASAHI GLASS CO LTD
Next Patent: BENZOPHENONE SKELETON-CONTAINING PEROXIDE, ITS PRODUCTION AND USE